Korean Circ J.  2018 May;48(5):430-432. 10.4070/kcj.2018.0085.

Effect of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Outcome

Affiliations
  • 1Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea. kikim907@snu.ac.kr

Abstract

No abstract available.


MeSH Terms

Dipeptidyl-Peptidase IV Inhibitors
Myocardial Infarction
Cardiovascular Diseases
Dipeptidyl Peptidase 4
Diabetes Mellitus, Type 2
Dipeptidyl-Peptidase IV Inhibitors
Dipeptidyl Peptidase 4

Reference

1. Preis SR, Hwang SJ, Coady S, et al. Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005. Circulation. 2009; 119:1728–1735.
Article
2. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352:837–853.
3. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008; 359:1577–1589.
Article
4. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009; 360:129–139.
Article
5. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007; 356:2457–2471.
Article
6. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet. 2009; 373:2125–2135.
Article
7. Smith RJ, Goldfine AB, Hiatt WR. Evaluating the cardiovascular safety of new medications for type 2 diabetes: time to reassess? Diabetes Care. 2016; 39:738–742.
Article
8. Ha KH, Kim B, Shin HS, et al. Comparative cardiovascular risks of dipeptidyl peptidase-4 inhibitors: analyses of real-world data in Korea. Korean Circ J. 2018; 48:395–405.
Article
9. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013; 369:1317–1326.
Article
Full Text Links
  • KCJ
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr